Point72 Asset Management
ELDN icon

Point72 Asset Management’s Eledon Pharmaceuticals ELDN Stock Holding History

Point72 Asset Management’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,095,000
Closed -$4.51M – 2168
2024
Q4 		$4.51M Buy
+1,095,000
New +$4.32M 0.01% 984
2022
Q4 		– Sell
-375,000
Closed -$1.03M – 1592
2022
Q3 		$1.03M Sell
375,000
-53,360
-12% -$170K ﹤0.01% 1051
2022
Q2 		$1.04M Sell
428,360
-127,535
-23% -$389K ﹤0.01% 1064
2022
Q1 		$2.19M Buy
555,895
+124,460
+29% +$483K 0.01% 863
2021
Q4 		$1.9M Buy
431,435
+221,945
+106% +$1.12M 0.01% 829
2021
Q3 		$1.29M Buy
209,490
+20,800
+11% +$145K 0.01% 829
2021
Q2 		$1.49M Buy
188,690
+63,690
+51% +$601K 0.01% 758
2021
Q1 		$1.34M Buy
+125,000
New +$1.89M 0.01% 777

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Point72 Asset Management's ELDN Position: Q1 2025 in Review

Point72 Asset Management sold out of Eledon Pharmaceuticals (ELDN) in Q1 2025, closing a stake of 1,095,000 shares — an estimated $4.51M sold.

Point72 Asset Management first reported a position in ELDN in Q1 2021 and held it in 8 quarters. The position peaked at $4.51M in Q4 2024. 83 funds tracked by Wall St. Rank hold ELDN as of Q1 2025.

  • Point72 Asset Management reported no remaining Eledon Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Point72 Asset Management sold 1,095,000 Eledon Pharmaceuticals shares in Q1 2025, an estimated $4.51M.
  • Point72 Asset Management first reported a position in Eledon Pharmaceuticals in Q1 2021 and held it in 8 quarters.
  • Point72 Asset Management's Eledon Pharmaceuticals position peaked at $4.51M in Q4 2024.
  • 83 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q1 2025.

Based on Point72 Asset Management's 13F filing for Q1 2025, filed 15 May 2025.